Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

80.17 +1.26 (+1.60%)
Official Closing Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 Next >
Alcon to Present at 2025 Baird Global Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSE - WOW), BankFinancial Corporation (Nasdaq - BFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)
From Brodsky & Smith LLC
Via GlobeNewswire
Alcon Agrees to Acquire STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
From Alcon Inc. Investors
Via Business Wire
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Alcon Inc. Investors
Via Business Wire
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
From Alcon Inc. Investors
Via Business Wire
Alcon Publishes Agenda for 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
From Alcon Inc. Investors
Via Business Wire
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
From Alcon Inc. Investors
Via Business Wire
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
From Alcon Inc. Investors
Via Business Wire
Alcon Agrees to Acquire LENSAR, Inc.
From Alcon Inc. Investors
Via Business Wire
Alcon to Host 2025 Capital Markets Day
From Alcon Inc. Investors
Via Business Wire
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
From Alcon Canada
Via Business Wire
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
From Alcon Inc. Investors
Via Business Wire
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
From Alcon Inc. Investors
Via Business Wire
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
From Alcon Inc. Investors
Via Business Wire
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
From Alcon Inc. Investors
Via Business Wire
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
From Alcon Inc. Investors
Via Business Wire
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.